Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting
08 Março 2022 - 6:57PM
Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company
committed to discovering and delivering the next generation of
precision cancer medicines, today announced that three abstracts
have been selected for presentation as posters at the American
Association for Cancer Research (AACR) 2022 Annual Meeting, taking
place from April 8-13, 2022, at the Ernest N. Morial Convention
Center in New Orleans, Louisiana, and online.
Details on Tango’s presentations at the AACR 2022 Annual
Meeting as follows:
Poster Title: TNG908 is an
MTAPnull-selective PRMT5 inhibitor that drives tumor regressions in
MTAP-deleted xenograft models across multiple
histologiesAbstract #: 3941e-Poster
Date and Time: Available Friday, April 8, 2022, 1:00 PM ET
In-Person Session Date and Time: Emerging New
Anticancer Agents; Poster Section 22; Wednesday, April 13, 2022, 9
– 12:30 PM CT
Poster Title: USP1 inhibitor synthetic
lethality in BRCA1-mutant cancer is driven by PCNA
ubiquitinationAbstract #: 2603e-Poster
Date and Time: Available Friday, April 8, 2022 1:00 PM ET
In-person Session Date and Time: DNA Damage
Response and Repair; Poster Section 22; Tuesday, April 12, 2022, 9
– 12:30 PM CT
Poster Title: UMIBB: A novel nonparametric
Bayesian method improves robustness and sensitivity of analysis in
pooled CRISPR-Cas9 screens leveraging unique molecular
identifiersAbstract #:1224e-Poster Date
and Time: Available Friday, April 8, 2022 1:00 PM ET
In-person Session Date and Time: New Algorithms
and Tools for Data Analysis; Section 29; Monday, April 11, 2022, 9
– 12:30 PM CT
About Tango Therapeutics
Tango Therapeutics is a biotechnology company dedicated to
discovering novel drug targets and delivering the next generation
of precision medicine for the treatment of cancer. Using an
approach that starts and ends with patients, Tango leverages the
genetic principle of synthetic lethality to discover and develop
therapies that take aim at critical targets in cancer. This
includes expanding the universe of precision oncology targets into
novel areas such as tumor suppressor gene loss and their
contribution to the ability of cancer cells to evade immune cell
killing. For more information, please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release may be considered
forward-looking statements. Forward-looking statements generally
relate to future events, Tango’s future operating performance,
goals, the anticipated benefits of therapies and combination
therapies (that include a Tango pipeline product), expectations,
beliefs and development objectives for Tango’s product pipeline. In
some cases, you can identify forward-looking statements by
terminology such as “may”, “should”, “expect”, “intend”, “will”,
“goal”, “estimate”, “anticipate”, “believe”, “predict”, “potential”
or “continue”, or the negatives of these terms or variations of
them or similar terminology. For example, statements concerning the
following include or constitute forward-looking statements:
anticipated benefits of Tango’s products, including TNG908 and its
USP1 inhibitor; TNG908 can drive tumor regression in cancer cells
and patients; the clinical benefits that may be realized by Tango’s
synthetic lethality platform and CRISPR screening tools; ; and the
expected timing of: (i) development candidate declaration for
certain targets, (ii) initiating IND-enabling studies; (iii) filing
INDs and (iv) clinical trial initiation. Such forward-looking
statements are subject to risks, uncertainties, and other factors
which could cause actual results to differ materially from those
expressed or implied by such forward looking statements. These
forward-looking statements are based upon estimates and assumptions
that, while considered reasonable by Tango and its management are
inherently uncertain. New risks and uncertainties may emerge from
time to time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to: benefits of product candidates seen in pre-clinical analyses
may not be evident when tested in clinical trials; the benefits of
Tango pipeline products and potential combination therapies that
are seen in pre-clinical experiments may not be present in clinical
trials or in use commercially or may not be safe and/or effective
in humans (and Tango or a third-party may not be able to obtain
approval or commercial sales of any monotherapy combination
therapies);Tango has limited experience with conducting clinical
trials and may not be able to commence the clinical trial when
expected and may not generate results in the anticipated timeframe
(or at all); Tango has a limited operating history and has not
generated any revenue to date from drug sales, and may never become
profitable; the Company may not be able to identify development
candidates on the schedule it anticipates due to technical,
financial or other reasons; the Company may not be able to file IND
for development candidates on time, or at all, due to technical or
financial reasons or otherwise, the Company may utilize cash
resources more quickly than anticipated; Tango will need to raise
capital in the future and if we are unable to raise capital when
needed or on attractive terms, we would be forced to delay, scale
back or discontinue some of our development programs or future
commercialization efforts; we may be unable to advance our
preclinical development programs into and through the clinic for
safety or efficacy reasons or commercialize our product candidates
or we may experience significant delays in doing so as a result of
factors beyond Tango’s control; Tango’s approach to the discovery
and development of product candidates is novel and unproven, which
makes it difficult to predict the time, cost of development, and
likelihood of successfully developing any products; Tango may not
identify or discover additional product candidates or may expend
limited resources to pursue a particular product candidate or
indication and fail to capitalize on product candidates or
indications that may be more profitable or for which there is a
greater likelihood of success; our products candidates may cause
adverse or other undesirable side effects that could, among other
things, delay or prevent regulatory approval; our dependence on
third parties for conducting clinical trials and producing drug
product; our ability to obtain and maintain patent and other
intellectual property protection for our technology and product
candidates or the scope of intellectual property protection
obtained is not sufficiently broad; and delays and other impacts on
product development and clinical trials from the COVID-19 pandemic.
Additional information concerning risks, uncertainties and
assumptions can be found in Tango’s filings with the SEC,
including the risk factors referenced in Tango’s Quarterly Report
on Form 10-Q filed with the SEC on November 9, 2021. You should not
place undue reliance on forward-looking statements in this
presentation, which speak only as of the date they are made and are
qualified in their entirety by reference to the cautionary
statements herein. Tango specifically disclaims any duty to update
these forward-looking statements.
Investor Contact:
Sam Martin/Michael BarronArgot
Partnerstango@argotpartners.com
Media Contact:
Joshua R. Mansbach Argot Partners tango@argotpartners.com
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024